Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2017

01-04-2017 | Short Communication

The General Expression Analysis of WTX Gene in Normal and Cancer Tissues

Authors: Yao-Yao Zhang, Qi-Ming Wang, Hui-Lin Niu, Xia Liu, Qing-Ling Zhang

Published in: Pathology & Oncology Research | Issue 2/2017

Login to get access

Abstract

WTX (Wilms’ tumor suppressor X chromosome) is a novel putative tumor suppressor gene in Wilms’ tumor of kidney, its expression and function in other human cancers had not been explored. This study detected the expression of WTX in 459 cases of 15 organs of cancers and adjacent normal tissues by using immunohistochemical staining (IHC), and validated them by in situ hybridization (ISH) and quantitative real-time reverse transcription PCR (qRT-PCR). IHC and ISH data showed that WTX protein was generally expressed in normal tissues, but reduced expression in corresponding cancers. This study demonstrated that WTX downregulation is a common phenomenon in human cancers, WTX might be a general tumor-suppressor gene and biological marker of multiple cancer tissues. Apart from kidney, stomach is another target tissue of WTX gene. The germline and somatic mutations of WTX were screened in 12 gastric cancer patients and identified in one cases (8.3%). Mutation in the WTX gene might be one of the reasons of WTX loss in gastric cancer patients.
Literature
1.
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA (2007) An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315(5812):642–645CrossRefPubMed
2.
Alexandrescu, S., S. Akhavanfard, M.H. Harris, and S.O. Vargas, Clinical, pathologic, and genetic features of Wilms tumors with WTX gene mutation. Pediatr Dev Pathol, 2016.
3.
X-ing Out Tumor Suppression. Science, 2007. 315: p. 569 h.
4.
5.
Kim MK, Min DJ, Rabin M, Licht JD (2011) Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants. Oncogene 30(7):832–842CrossRefPubMed
6.
Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Minaur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Ades LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, Robertson SP (2009) Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet 41(1):95–100CrossRefPubMed
7.
Fujita A, Ochi N, Fujimaki H, Muramatsu H, Takahashi Y, Natsume J, Kojima S, Nakashima M, Tsurusaki Y, Saitsu H, Matsumoto N, Miyake N (2014) A novel WTX mutation in a female patient with osteopathia striata with cranial sclerosis and hepatoblastoma. Am J Med Genet A 164A(4):998–1002CrossRefPubMed
8.
Comai G, Boutet A, Neirijnck Y, Schedl A (2010) Expression patterns of the Wtx/Amer gene family during mouse embryonic development. Dev Dyn 239(6):1867–1878CrossRefPubMed
9.
He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, Deng Y, Yang L, Li J, Cai J, Qiu L, Wen K, Xu X, Jiang S (2006) Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 210(3):288–297CrossRefPubMed
10.
Qingling Z, Lina Y, Li L, Shuang W, Yufang Y, Yi D, Divakaran J, Xin L, Yanqing D (2011) LMP1 antagonizes WNT/beta-catenin signalling through inhibition of WTX and promotes nasopharyngeal dysplasia but not tumourigenesis in LMP1(B95-8) transgenic mice. J Pathol 223(5):574–583CrossRefPubMed
11.
Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT (2007) Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 316(5827):1043–1046CrossRefPubMed
12.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25(4):402–408CrossRefPubMed
13.
Armat M, Ramezani F, Molavi O, Sabzichi M, Samadi N (2016) Six family of homeobox genes and related mechanisms in tumorigenesis protocols. Tumori:0
14.
Kress E, Skah S, Sirakov M, Nadjar J, Gadot N, Scoazec JY, Samarut J, Plateroti M (2010) Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis. Gastroenterology 138(5):1863–1874CrossRefPubMed
15.
Rivlin N, Brosh R, Oren M, Rotter V (2011) Mutations in the p53 tumor suppressor Gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2(4):466–474CrossRefPubMedPubMedCentral
16.
Holloway KR, Sinha VC, Bu W, Toneff M, Dong J, Peng Y, Li Y (2016) Targeting oncogenes into a defined subset of mammary cells demonstrates that the initiating oncogenic mutation defines the resulting tumor phenotype. Int J Biol Sci 12(4):381–388CrossRefPubMedPubMedCentral
17.
Zhou QM, Li W, Zhang X, Chen YB, Chen XC, Guan YX, Ding Y, Wen XZ, Xia Q, Zhou Q, Peng RQ, Hou JH, Zhu XF, Zeng YX, Zhang XS (2012) The mutation profiles of common oncogenes involved in melanoma in southern China. J Invest Dermatol 132(7):1935–1937CrossRefPubMed
18.
Evangelisti C, de Biase D, Kurelac I, Ceccarelli C, Prokisch H, Meitinger T, Caria P, Vanni R, Romeo G, Tallini G, Gasparre G, Bonora E (2015) A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC Cancer 15:157CrossRefPubMedPubMedCentral
19.
Perotti D, Gamba B, Sardella M, Spreafico F, Terenziani M, Collini P, Pession A, Nantron M, Fossati-Bellani F, Radice P (2008) Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors. Oncogene 27(33):4625–4632CrossRefPubMed
20.
Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE, Robertson SP (2010) WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet 47(11):791–794CrossRefPubMed
21.
Scheel SK, Porzner M, Pfeiffer S, Ormanns S, Kirchner T, Jung A (2010) Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers. BMC Cancer 10:413CrossRefPubMedPubMedCentral
22.
Chung NG, Kim MS, Chung YJ, Yoo NJ, Lee SH (2008) Tumor suppressor WTX gene mutation is rare in acute leukemias. Leuk Lymphoma 49(8):1616–1617CrossRefPubMed
23.
Zilberman D, Coleman-Derr D, Ballinger T, Henikoff S (2008) Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 456(7218):125–129CrossRefPubMedPubMedCentral
24.
Liu X, Wang Q, Niu H, Yang X, Sun J, Zhang Q, Ding Y (2013) Promoter methylation of Wilms’ tumor gene on the X- chromosome in gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao 33(3):318–321PubMed
Metadata
Title
The General Expression Analysis of WTX Gene in Normal and Cancer Tissues
Authors
Yao-Yao Zhang
Qi-Ming Wang
Hui-Lin Niu
Xia Liu
Qing-Ling Zhang
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0168-0

Other articles of this Issue 2/2017

Pathology & Oncology Research 2/2017 Go to the issue

Erratum

Erratum to: Genetic Screening in Pheochromocytoma/Paraganglioma

Original Article

Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases

Original Article

Low Expression LncRNA TUBA4B is a Poor Predictor of Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer

Short Communication

The Missing Link in the Diagnostic Pathway of Prostate Cancer

Original Article

Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature

Letter to the Editor

Frameshift Mutation of FXR1 Encoding a RNA-Binding Protein in Gastric and Colorectal Cancers with Microsatellite Instability
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits